TCT 2011: Game-changing valve approved in the US
This is a preview of restricted content.
- If you are an Advisory Board member, please log in.
- If you are logged in and still see this message, the content is outside your memberships portfolio, and we invite you to learn more by contacting us.
- If you are not an Advisory Board member and wish to learn more, please contact us.
Topics: Service Lines, Market Trends, Strategy, Planning, Cardiovascular
Joseph McCaffrey, Technology Insights
November 17, 2011
Last week, more than 15,000 interventional cardiologists and cardiac surgeons from around the world travelled to the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, Calif. As a technology-focused conference, TCT is the largest annual interventional cardiology meeting held in the U.S. and offers clinical symposia, new device presentations, and late-breaking trials pertinent to the cardiovascular community.
While the conference has been dominated by drug-eluting stent news in past years, structural heart interventions, heart failure therapies, and future pipeline concerns all received significant coverage this year.
